Fig. 1: Progression-free survival by bone marrow status.

Kaplan–Meier plots show progression-free survival by baseline bone marrow blasts (<50%, 50–90%, and >90%) for patients in the (a) InO arm and (b) SC arm. BMB bone marrow blasts, InO inotuzumab ozogamicin, PFS progression-free survival, SC standard of care chemotherapy.